Piramal Pharma Share Price Drops 3.36% on May 15; PAT Surges 411% YoY in FY25 Results

Piramal Pharma Limited (PPL) announced its standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2025.

Post the announcement, on May 15, 2025, Piramal Pharma share price (NSE: PPLPHARMA) opened at ₹223.30, up from its previous close of ₹219.04. At 10:33 AM, the share price of Piramal Pharma was trading at ₹211.69, down by 3.36% on the NSE.

Steady Revenue Growth Backed by CDMO Performance

For Q4 FY25, PPL recorded an 8% year-on-year (YoY) growth in revenue from operations. On a full-year basis, revenue rose by 12% YoY in FY25. The growth was largely driven by the on-patent commercial manufacturing segment within the CDMO business, which continues to be a key contributor to the company’s topline.

EBITDA Rises on Operational Leverage and Cost Optimisation

EBITDA grew by 8% YoY in Q4 FY25 and 15% YoY for the full year. This was supported by ongoing operational excellence programs, cost optimisation initiatives, and better utilization of existing capacities. The company’s efforts to enhance productivity and streamline operations are paying off in terms of improved margins.

PAT Sees Upsurge

Profit After Tax (PAT), post exceptional items, jumped 52% YoY to ₹154 crore in Q4 FY25 compared to ₹101 crore in the same quarter last year. For FY25, PAT surged by a remarkable 411% YoY to ₹91 crore from ₹18 crore in FY24, showcasing a significant turnaround in bottom-line performance.

Financial Strength Improves

PPL also strengthened its balance sheet during the year. The Net Debt-to-EBITDA ratio improved to 2.7x in FY25, down from 5.6x in FY23.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth.”

She further added, “During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business. We believe, we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE.”

Also Read: Piramal Pharma Plans Major US Expansion with $90 Million Investment!

Conclusion

Piramal Pharma Limited has ended FY25, with growth in revenue, profitability, and financial health. With continued focus on its CDMO business and operational discipline, the company appears well-positioned for sustained future growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.